Status and Quality of Guidelines for Therapeutic Drug Monitoring Based on AGREE II Instrument

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 2023 Jul 25

PMID 37490190

Authors

Zhan-Miao Yi

Xinya Li

Zhitong Wang

Jiguang Qin

Dan Jiang

Panhui Tian

Ping Yang

Rongsheng Zhao

Affiliations

Soon will be listed here.

Abstract

Background: With the progress of therapeutic drug monitoring (TDM) technology and the development of evidence-based medicine, many guidelines were developed and implemented in recent decades.

Objective: The aim was to evaluate the current status of TDM guidelines and provide suggestions for their development and updates based on Appraisal of Guidelines for Research and Evaluation (AGREE) II.

Methods: The TDM guidelines were systematically searched for among databases including PubMed, Embase, China National Knowledge Infrastructure, Wanfang Data, and the Chinese biomedical literature service system and the official websites of TDM-related associations. The search period was from inception to 6 April 2023. Four researchers independently screened the literature and extracted data. Any disagreement was discussed and reconciled by another researcher. The quality of guidelines was assessed using the AGREE II instrument.

Results: A total of 92 guidelines were included, including 57 technical guidelines, three management guidelines, and 32 comprehensive guidelines. The number of TDM guidelines has gradually increased since 1979. The United States published the most guidelines (20 guidelines), followed by China (15 guidelines) and the United Kingdom (ten guidelines), and 23 guidelines were developed by international organizations. Most guidelines are aimed at adult patients only, while 28 guidelines include special populations. With respect to formulation methods, there are 23 evidence-based guidelines. As for quality evaluation results based on AGREE II, comprehensive guidelines scored higher (58.16%) than technical guidelines (51.36%) and administrative guidelines (50.00%).

Conclusion: The number of TDM guidelines, especially technical and comprehensive ones, has significantly increased in recent years. Most guidelines are confronted with the problems of unclear methodology and low quality of evidence according to AGREE II. More evidence-based research on TDM and high-quality guideline development is recommended to promote individualized therapy.

Citing Articles

Interprofessional Therapeutic Drug Monitoring of Piperacillin/Tazobactam Enhances Care for Patients with Acute-on-Chronic Liver Failure in the ICU: A Retrospective Observational Pilot Study.

Schmid S, Zimmermann K, Koch C, Mester P, Athanasoulas G, Buttenschoen J Antibiotics (Basel). 2025; 14(2).

PMID: 40001445 PMC: 11851559. DOI: 10.3390/antibiotics14020202.

Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes.

Biso L, Aringhieri S, Carli M, Scarselli M, Longoni B Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794212 PMC: 11124530. DOI: 10.3390/ph17050642.

Interprofessional Therapeutic Drug Monitoring of Carbapenems Improves ICU Care and Guideline Adherence in Acute-on-Chronic Liver Failure.

Schmid S, Koch C, Zimmermann K, Buttenschoen J, Mehrl A, Pavel V Antibiotics (Basel). 2023; 12(12).

PMID: 38136763 PMC: 10740747. DOI: 10.3390/antibiotics12121730.

References

Zeng L, Yi Q, Huang L, Chen W, Men P, Zhang J . The guideline for therapeutic drug monitoring guidelines development. J Evid Based Med. 2022; 15(3):272-283. DOI: 10.1111/jebm.12486. View

Wicha S, Martson A, Nielsen E, Koch B, Friberg L, Alffenaar J . From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics. Clin Pharmacol Ther. 2021; 109(4):928-941. DOI: 10.1002/cpt.2202. View

Papamichael K, Afif W, Drobne D, Dubinsky M, Ferrante M, Irving P . Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022; 7(2):171-185. PMC: 10187071. DOI: 10.1016/S2468-1253(21)00223-5. View

Mueller-Schoell A, Groenland S, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R . Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol. 2020; 77(4):441-464. PMC: 7935845. DOI: 10.1007/s00228-020-03014-8. View

Zeng M, Yi Q, Zeng L, Chen Z, Mi X, Song H . Quality of therapeutic drug monitoring guidelines is suboptimal: an evaluation using the Appraisal of Guidelines for Research and Evaluation II instrument. J Clin Epidemiol. 2019; 120:47-58. DOI: 10.1016/j.jclinepi.2019.10.007. View

Brouwers M, Kho M, Browman G, Burgers J, Cluzeau F, Feder G . Development of the AGREE II, part 1: performance, usefulness and areas for improvement. CMAJ. 2010; 182(10):1045-52. PMC: 2900328. DOI: 10.1503/cmaj.091714. View

Brouwers M, Kho M, Browman G, Burgers J, Cluzeau F, Feder G . Development of the AGREE II, part 2: assessment of validity of items and tools to support application. CMAJ. 2010; 182(10):E472-8. PMC: 2900368. DOI: 10.1503/cmaj.091716. View

Burls A . AGREE II-improving the quality of clinical care. Lancet. 2010; 376(9747):1128-9. DOI: 10.1016/S0140-6736(10)61034-3. View

Lenzer J, Hoffman J, Furberg C, Ioannidis J . Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ. 2013; 347:f5535. DOI: 10.1136/bmj.f5535. View

10.

Alonso-Coello P, Irfan A, Sola I, Gich I, Delgado-Noguera M, Rigau D . The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies. Qual Saf Health Care. 2010; 19(6):e58. DOI: 10.1136/qshc.2010.042077. View

11.

Qaseem A, Forland F, Macbeth F, Ollenschlager G, Phillips S, van der Wees P . Guidelines International Network: toward international standards for clinical practice guidelines. Ann Intern Med. 2012; 156(7):525-31. DOI: 10.7326/0003-4819-156-7-201204030-00009. View

12.

Hammett-Stabler C, Johns T . Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry. Clin Chem. 1998; 44(5):1129-40. View

13.

Acosta E, Gerber J . Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses. 2002; 18(12):825-34. DOI: 10.1089/08892220260190290. View

14.

Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R . Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002; 16 Suppl 1:S5-37. DOI: 10.1097/00002030-200203001-00002. View

15.

Boffito M, Acosta E, Burger D, Fletcher C, Flexner C, Garaffo R . Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir Ther. 2005; 10(3):375-92. View

16.

Boffito M, Acosta E, Burger D, Fletcher C, Flexner C, Garaffo R . Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther. 2005; 10(4):469-77. View

17.

Higgins N, Tseng A, Sheehan N, la Porte C . Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice. Can J Hosp Pharm. 2012; 62(6):500-9. PMC: 2827030. DOI: 10.4212/cjhp.v62i6.849. View

18.

Chau M, Kong D, Van Hal S, Urbancic K, Trubiano J, Cassumbhoy M . Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Intern Med J. 2014; 44(12b):1364-88. DOI: 10.1111/imj.12600. View

19.

He N, Su S, Ye Z, Du G, He B, Li D . Evidence-based Guideline for Therapeutic Drug Monitoring of Vancomycin: 2020 Update by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Clin Infect Dis. 2020; 71(Suppl 4):S363-S371. DOI: 10.1093/cid/ciaa1536. View

20.

Lin B, Hu Y, Xu P, Xu T, Chen C, He L . Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front Public Health. 2022; 10:967311. PMC: 9399604. DOI: 10.3389/fpubh.2022.967311. View